Marker Therapeutics, Inc.

Monthly Archives: April 2016

TapImmune to Present at the 3rd Annual Growth Capital Expo in Las Vegas on May 4, 2016

JACKSONVILLE, FL, April 28, 2016 / TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced it will be presenting at the 3rd Annual Growth Capital Expo to be held on May 3rd – 5th, 2016 at Caesars Palace in Las Vegas, Nevada.
Read More

TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute

JACKSONVILLE, Florida, April 21, 2016 /PRNewswire/ – Study to commence Q2 2016 at Sloan Kettering Institute Cancer vaccine and checkpoint inhibitor combination to be evaluated in platinum-resistant ovarian cancer patients TapImmune,Inc.
Read More

TapImmune Completes GMP Manufacturing and Release of TPIV 200 Vaccine

Doses for use at Mayo Clinic and other clinical sites Stable, easily reconstituted product contains five folate receptor alpha peptides in a single vial TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer &
Read More